Charles Schwab Investment Management Inc Prothena Corp Public LTD CO Transaction History

Charles Schwab Investment Management Inc

  • $519 Billion
  • Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 327,139 shares of PRTA stock, worth $7.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
327,139
Previous 318,905 2.58%
Holding current value
$7.03 Million
Previous $7.9 Million 14.52%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$19.54 - $26.15 $160,892 - $215,319
8,234 Added 2.58%
327,139 $6.75 Million
Q1 2024

May 08, 2024
BUY
$24.75 - $40.66 $140,456 - $230,745
5,675 Added 1.81%
318,905 $7.9 Million
Q4 2023

Feb 06, 2024
BUY
$32.31 - $52.32 $151,630 - $245,537
4,693 Added 1.52%
313,230 $11.4 Million
Q3 2023

Nov 08, 2023
SELL
$47.3 - $70.6 $186,645 - $278,587
-3,946 Reduced 1.26%
308,537 $14.9 Million
Q2 2023

Aug 09, 2023
BUY
$48.26 - $78.59 $652,089 - $1.06 Million
13,512 Added 4.52%
312,483 $21.3 Million
Q1 2023

May 11, 2023
SELL
$46.97 - $58.27 $88,256 - $109,489
-1,879 Reduced 0.62%
298,971 $14.5 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $786,371 - $982,020
15,108 Added 5.29%
300,850 $18.1 Million
Q3 2022

Nov 14, 2022
BUY
$25.16 - $60.63 $207,997 - $501,228
8,267 Added 2.98%
285,742 $17.3 Million
Q2 2022

Aug 15, 2022
SELL
$22.73 - $39.98 $157,450 - $276,941
-6,927 Reduced 2.44%
277,475 $7.53 Million
Q1 2022

May 13, 2022
BUY
$30.27 - $49.22 $871,412 - $1.42 Million
28,788 Added 11.26%
284,402 $10.4 Million
Q4 2021

Feb 11, 2022
BUY
$42.11 - $73.26 $585,286 - $1.02 Million
13,899 Added 5.75%
255,614 $12.6 Million
Q3 2021

Nov 16, 2021
BUY
$48.2 - $78.89 $1.68 Million - $2.75 Million
34,889 Added 16.87%
241,715 $17.2 Million
Q2 2021

Aug 16, 2021
BUY
$21.63 - $57.65 $442,009 - $1.18 Million
20,435 Added 10.96%
206,826 $10.6 Million
Q1 2021

May 17, 2021
BUY
$11.0 - $28.24 $42,372 - $108,780
3,852 Added 2.11%
186,391 $4.68 Million
Q4 2020

Feb 16, 2021
SELL
$10.12 - $13.94 $4,270 - $5,882
-422 Reduced 0.23%
182,539 $2.19 Million
Q3 2020

Nov 13, 2020
SELL
$9.93 - $13.47 $542,446 - $735,825
-54,627 Reduced 22.99%
182,961 $1.83 Million
Q2 2020

Aug 14, 2020
SELL
$9.56 - $12.51 $46,060 - $60,273
-4,818 Reduced 1.99%
237,588 $2.49 Million
Q1 2020

May 15, 2020
BUY
$7.54 - $15.77 $25,636 - $53,618
3,400 Added 1.42%
242,406 $2.59 Million
Q4 2019

Feb 07, 2020
BUY
$7.48 - $17.01 $40,317 - $91,683
5,390 Added 2.31%
239,006 $3.78 Million
Q3 2019

Nov 08, 2019
SELL
$6.89 - $10.45 $4,988 - $7,565
-724 Reduced 0.31%
233,616 $1.83 Million
Q2 2019

Aug 09, 2019
BUY
$8.85 - $12.49 $135,413 - $191,109
15,301 Added 6.99%
234,340 $2.48 Million
Q1 2019

May 14, 2019
SELL
$10.32 - $14.49 $12,693 - $17,822
-1,230 Reduced 0.56%
219,039 $2.66 Million
Q4 2018

Feb 14, 2019
BUY
$8.73 - $13.74 $164,813 - $259,397
18,879 Added 9.37%
220,269 $2.27 Million
Q3 2018

Nov 13, 2018
SELL
$12.7 - $15.79 $43,141 - $53,638
-3,397 Reduced 1.66%
201,390 $2.64 Million
Q2 2018

Aug 08, 2018
BUY
$10.99 - $44.21 $324,567 - $1.31 Million
29,533 Added 16.85%
204,787 $2.99 Million
Q1 2018

May 07, 2018
SELL
$27.95 - $45.04 $185,168 - $298,390
-6,625 Reduced 3.64%
175,254 $6.43 Million
Q4 2017

Jan 17, 2018
BUY
$35.44 - $63.76 $329,627 - $593,031
9,301 Added 5.39%
181,879 $6.82 Million
Q3 2017

Nov 13, 2017
BUY
$53.83 - $67.75 $9.29 Million - $11.7 Million
172,578
172,578 $11.2 Million

Others Institutions Holding PRTA

# of Institutions
182
Shares Held
42.7M
Call Options Held
77.7K
Put Options Held
92.7K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $1.01B
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email